Cryoport, Inc.
General ticker "CYRX" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $374.1M (TTM average)
Cryoport, Inc. follows the US Stock Market performance with the rate: 58.9%.
Estimated limits based on current volatility of 3.0%: low 9.17$, high 9.74$
Factors to consider:
- Total employees count: 1186 (+1.4%) as of 2024
- North and South America accounted for 55.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Product liability, Demand forecasting, Market competition, Acquisition/divestiture risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.59$, 10.19$]
- 2025-12-31 to 2026-12-31 estimated range: [4.14$, 9.29$]
Financial Metrics affecting the CYRX estimates:
- Negative: with PPE of -6.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.28 <= 0.33
- Positive: -8.75 < Industry operating profit margin (median), % of 1.31
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 5.80
- Positive: Interest expense per share per price, % of 1.08 <= 3.41
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 46.34 > -0.66
- Positive: 41.86 < Shareholder equity ratio, % of 57.13 <= 63.39
Short-term CYRX quotes
Long-term CYRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $222.61MM | $233.25MM | $228.38MM |
| Operating Expenses | $240.44MM | $348.41MM | $359.25MM |
| Operating Income | $-17.83MM | $-115.16MM | $-130.87MM |
| Non-Operating Income | $-256.01MM | $15.81MM | $17.39MM |
| Interest Expense | $4.69MM | $5.50MM | $4.11MM |
| R&D Expense | $16.84MM | $18.04MM | $17.71MM |
| Income(Loss) | $-273.84MM | $-99.35MM | $-113.48MM |
| Taxes | $1.69MM | $0.24MM | $1.28MM |
| Profit(Loss)* | $-513.72MM | $-37.33MM | $-99.59MM |
| Stockholders Equity | $555.84MM | $489.02MM | $401.90MM |
| Inventory | $27.68MM | $26.21MM | $22.47MM |
| Assets | $1,038.75MM | $957.74MM | $703.49MM |
| Operating Cash Flow | $-1.85MM | $-0.76MM | $-16.32MM |
| Capital expenditure | $24.20MM | $44.90MM | $17.25MM |
| Investing Cash Flow | $-59.68MM | $36.05MM | $176.81MM |
| Financing Cash Flow | $-39.17MM | $-23.80MM | $-161.53MM |
| Earnings Per Share** | $-11.19 | $-0.76 | $-2.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.